Pharmacogenetic Data With Clinical Outcomes Should Be Described In Label
Pharmacogenetic variations with demonstrated clinical outcomes should be discussed in drug labeling, members of FDA's Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science said at its April 23 meeting
You may also be interested in...
FDA is forming a pharmacogenomics advisory committee to handle voluntary genomic data submissions, Office of Clinical Pharmacology & Biopharmaceutics Director Lawrence Lesko, PhD, said
Lilly's Strattera review provides one example of a successful effort by a sponsor to address potential safety issues for a pending application without agreeing to a risk management program
GlaxoSmithKline's Purinethol (mercaptopurine) should include labeling recommending use of pharmacogenetic testing to guide dosing, the Clinical Pharmacology Subcommittee of FDA's Pharmaceutical Science Advisory Committee concluded at its Oct. 23 meeting